Skip to main navigation Skip to search Skip to main content

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma

  • H. A.F. Stessman
  • , A. Lulla
  • , T. Xia
  • , A. Mitra
  • , T. Harding
  • , A. Mansoor
  • , C. L. Myers
  • , B. G. Van Ness
  • , N. G. Dolloff

Research output: Contribution to journal › Letter › peer-review

Original languageEnglish (US)
Pages (from-to)2263-2267
Number of pages5
JournalLeukemia
Volume28
Issue number11
DOIs
StatePublished - Nov 2014

Bibliographical note

Funding Information:
BVN receives research support from Millennium Pharmaceuticals, Inc., Cambridge, MA, and Onyx Pharmaceuticals, Inc., South San Francisco, CA, USA. The remaining authors declare no conflict of interest.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this